Jax DiEugenio

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

The FDA has granted fast track designation to 4A10 for relapsed/refractory ALL.

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Phase 2 data showed high 2-year survival and deep MRD-negative remissions with a CD22/CD19 CAR T-cell therapy and ASCT “sandwich” approach in B-ALL.

OncoMate MSI Dx was approved by the FDA to identify patients with MSS endometrial cancer who may be eligible for pembrolizumab plus lenvatinib.

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

Anwar Saeed, MD, discusses findings of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer.

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

Akriti Jain, MD, highlights the evolving role of JAK inhibitors in managing polycythemia vera and myelofibrosis and efforts to optimize treatment sequencing.

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

Martin Dietrich, MD, PhD, discusses how zongertinib offers a new targeted option for HER2-mutant NSCLC, yielding durable responses and strong CNS activity.

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Efrat Dotan, MD, discusses patient factors to consider during treatment planning for metastatic pancreatic cancer.

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.

Jonathan Riess, MD, discusses data for IO102-IO103 plus pembrolizumab in advanced HSNCC and NSCLC with high PD-L1 expression.

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.